Teva Pharmaceutical Industries (TEVA) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$13.8 billion.
- Teva Pharmaceutical Industries' Retained Earnings rose 929.94% to -$13.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$13.8 billion, marking a year-over-year increase of 929.94%. This contributed to the annual value of -$13.8 billion for FY2025, which is 929.94% up from last year.
- Teva Pharmaceutical Industries' Retained Earnings amounted to -$13.8 billion in Q4 2025, which was up 929.94% from -$14.2 billion recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year Retained Earnings high stood at -$2.4 billion for Q2 2021, and its period low was -$15.2 billion during Q4 2024.
- Its 5-year average for Retained Earnings is -$10.0 billion, with a median of -$13.6 billion in 2023.
- Its Retained Earnings has fluctuated over the past 5 years, first surged by 7638.79% in 2021, then tumbled by 40621.99% in 2024.
- Over the past 5 years, Teva Pharmaceutical Industries' Retained Earnings (Quarter) stood at -$2.7 billion in 2021, then fell by 5.78% to -$2.8 billion in 2022, then plummeted by 376.89% to -$13.5 billion in 2023, then fell by 12.11% to -$15.2 billion in 2024, then grew by 9.3% to -$13.8 billion in 2025.
- Its Retained Earnings stands at -$13.8 billion for Q4 2025, versus -$14.2 billion for Q3 2025 and -$14.7 billion for Q2 2025.